ROCHESTER, Minn.–(BUSINESS WIRE)–INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapiesROCHESTER, Minn.–(BUSINESS WIRE)–INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies

INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic™ in Advanced Wound Care

4 min read

ROCHESTER, Minn.–(BUSINESS WIRE)–INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has agreed to INTENT’s Initial Pediatric Study Plan (iPSP) for PEP Biologic™ under IND 019567, supporting the company’s request for a full pediatric waiver for its forthcoming Biologics License Application (BLA).

FDA’s agreement reflects alignment that pediatric studies are not required for PEP Biologic’s flagship indication, diabetic foot ulcers (DFU) which is initiating a pivotal trial in 2026. The agreed iPSP provides regulatory clarity and removes the requirement to conduct clinical studies in the pediatric population as part of the DFU development program, contingent upon biologic licensure.

“FDA alignment on our pediatric study plan is another important regulatory milestone achieved as we advance PEP Biologic toward late-stage clinical development and eventual BLA submission,” said Suneet Varma, Chief Executive Officer of INTENT Biologics. “This agreement allows us to remain fully focused on delivering a first-in-class biologic therapy for adult patients suffering from DFU, one of many different chronic, non-healing wounds with significant unmet medical need, while maintaining a clear and efficient regulatory pathway.”

The pediatric waiver agreement follows the FDA’s recent Fast Track designation for PEP Biologic in diabetic foot ulcers and further strengthens INTENT’s regulatory position as the company prepares for late-stage clinical development and registration-enabling studies. Together, these achieved regulatory milestones support an efficient development strategy aligned with FDA expectations for serious adult-onset conditions where pediatric studies are impossible or highly impractical.

PEP Biologic is a platelet-derived exosome biologic designed to deliver regenerative signaling messages that modulate immune responses and promote tissue repair, supporting resolution of inflammation and tissue regeneration. INTENT Biologics is advancing PEP Biologic into clinical development for diabetic foot ulcers, chronic radiation ulcers, and advanced wound care indications based on a proprietary exosome platform originating from RION.

About PEP Biologic™

PEP Biologic (Purified Exosome Product) is a first-in-class exosome therapeutic discovered through Mayo Clinic Van Cleve Cardiac Regenerative Medicine Program and developed on RION’s industry-leading platelet-derived exosome biomanufacturing platform. Packaged as a shelf-stable lyophilized powder, each dose contains regenerative exosomes that deliver polyvalent biologic signals to induce tissue regeneration and regulate immune responses for accelerated healing. With a novel mechanism of action that reduces hyper-inflammation, regulates immune response and repairs & regenerates tissue, PEP Biologic is being advanced by INTENT Biologics into pivotal clinical trials for a range of advanced wound care indications where current treatments fail to address the underlying biology.

About INTENT Biologics

INTENT Biologics is a clinical-stage biotechnology company dedicated to developing first-in-class exosome-based therapeutics in Advanced Wound Care. Spun out of RION, a global leader in regenerative exosome science, and built on more than two decades of research at the Mayo Clinic, INTENT is advancing PEP Biologic into late-stage clinical development for multiple indications in advanced tissue regeneration. Headquartered in Minnesota, the company is focused on “revolutionizing and replacing” standards of care in chronic wounds by harnessing regenerative exosomes to treat diseases with significant unmet need. More information can be found at www.intent.bio.

About RION

RION is a clinical-stage regenerative medicine company founded out of the Mayo Clinic after two decades of stem cell and exosome research and innovation. RION is the global leader in isolating and mass-producing platelet-derived regenerative exosomes into a proprietary therapeutic platform to produce Purified Exosome Product (PEP), a shelf-stable biologic designed to activate the body’s natural healing processes. RION is advancing a deep pipeline with clinical and preclinical programs in diabetic foot ulcers, knee osteoarthritis, musculoskeletal injury, dermatologic conditions, pulmonary disease, cardiovascular health, and women’s health. RION’s regenerative PEP technology will be integral to the therapeutic exosome revolution. More information can be found at www.riontx.com.

Contacts

Investor Relations
[email protected]

Market Opportunity
PEP Logo
PEP Price(PEP)
$0.000233
$0.000233$0.000233
+1.17%
USD
PEP (PEP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Water150 Unveils Historical Satra Brunn Well: The Original Source of 150 Years of Premium Quality Spring Water Hydration

Water150 Unveils Historical Satra Brunn Well: The Original Source of 150 Years of Premium Quality Spring Water Hydration

The post Water150 Unveils Historical Satra Brunn Well: The Original Source of 150 Years of Premium Quality Spring Water Hydration appeared on BitcoinEthereumNews.com. Water150, the project developed by the Longhouse Foundation to reserve access to premium spring water through a transparent, blockchain-based ecosystem of natural water springs, is excited to introduce its first natural water well, Satra Brunn.  The Sätra Brunn well is one of Sweden’s oldest and best-preserved natural spring water wells, located in a 324-year-old Swedish village. Every water source added to the network will be measured according to the pedigree and based on the foundations of the historically reliable Satra Brunn natural spring, a well that has endured since the 18th century.   The Satra Brunn well secures the first 66 million liters of the annually replenished mineral water supply, starting in January 2027, for the next 150 years. Each liter of water secured in the Satra Brunn well is fully backed by a corresponding Water150 token, issued on the Ethereum blockchain by the Longhouse Water S.A., a Luxembourg public limited liability company.  Hence, the first batch of 66 million Water150 tokens to enter circulation will fully back the annual supply from the Satra Brunn well.  The project uses blockchain technology as a barrierless and transparent ecosystem to connect users to naturally filtered, high-quality, and sustainably managed drinking water per year for at least 150 years, starting in 2027. The amount of Water150 tokens in circulation is a verifiable measure of the volume of annual water flow available within the ecosystem, audited by independent third parties. The W150 token is one of the first real-world asset (RWA) utility tokens to get the full approval of the European Securities and Markets Authority (ESMA), the body responsible for the Markets in Crypto-Assets Regulation (MiCAR), a cryptocurrency regulatory standard recognized and adopted throughout Europe. Water150 is building a global network of 1,000 premium mineral water sources like Satra Brunn, managed according to the high…
Share
BitcoinEthereumNews2025/09/19 19:41
Amazon signs AI and cloud partnership to accelerate growth

Amazon signs AI and cloud partnership to accelerate growth

Prosus and Amazon have signed a multi-year deal with AWS to consolidate cloud and AI contracts and save costs.
Share
Cryptopolitan2026/02/04 18:05
Senate Democrats Forge Ahead with U.S. Crypto Regulation Efforts

Senate Democrats Forge Ahead with U.S. Crypto Regulation Efforts

The long-stalled CLARITY Act, designed to regulate the U.S. cryptocurrency market, is back in the spotlight as Senate Democrats quietly resume discussions.Continue
Share
Coinstats2026/02/04 18:08